| Summary: | 碩士 === 高雄醫學大學 === 醫學檢驗生物技術學研究所 === 97 === Objectives: Damage to breast epithelium by reactive oxygen species is important in the initiation and promotion of cells to neoplastic growth. Therefore, this study investigated the genomic polymorphisms of metabolic enzymes, including detoxification and oxidative stress-related enzymes, associated with the risk of breast cancer.
Materials and Methods: 5ml of EDTA blood was taken from 260 patients admitted to breast cancer surgery from Kaohsiung Medical University Hospital and 224 controls. Genomic polymorphisms of detoxification enzymes, including CYP2E1, GSTM1, and oxidative stress related-enzymes, including manganese superoxide dismutase (MnSOD) , glutathione peroxidase1 (GPx1), myeloperoxidase (MPO）, and catalase 【CAT -15A>T, and CAT -262C>T】were analyzed.
Results: ①Compared with the subjects with the CYP2E1 -1053C>T CC genotype, those with the CYP2E1 -1053C>T TT genotype have a decreased risk of breast cancer (OR=0.26, p<0.05). In addition, those with the MnSOD 1183T>C C carrier rather than those with the MnSOD 1183T>C wild-type were predisposed to having a decreased risk of breast cancer, regardless of their allele, genotype (CC) and phenotype frequencies.（OR=0.41, 0.57 and 0.58 respectively, p<0.005） Furthermore, those with the GPx1 Pro198Leu T carrier rather than those with the GPx1 Pro198Leu wild-type were predisposed to having a decreased risk of breast cancer, regardless of their allele, genotype (CT) and phenotype frequencies. (OR=0.17, 0.15 and 0.19 respectively, p<0.001).② Those with the combimed genotypes for the CYP2E1 -1053C>T CC and MnSOD 1183T>C C carrier, and the combimed genotypes for the CYP2E1 -1053C>T T carrier and MnSOD 1183T>C C carrier rather than those with the CYP2E1 -1053C>T CC and MnSOD 1183T>C TT genotypes were predisposed to having a decreased risk of breast cancer (OR=0.60 and 0.46 respectively, p<0.05 ); those with the combimed genotypes for the CYP2E1 -1053C>T CC and GPx1 Pro198Leu T carrier, and the combimed genotypes for the CYP2E1 -1053C>T T carrier and GPx1Pro198Leu T carrier rather than those with the CYP2E1 -1053C>T CC and GPx1Pro198Leu CC genotypes were predisposed to having a decreased risk of breast cancer (OR=0.12 and 0.18 respectively, p<0.001 ). ③ Those with the combimed genotypes for the MnSOD 1183T>C C carrier and GSTM1 null-type rather than those with the MnSOD 1183T>C TT and GSTM1 wild-type genotypes were predisposed to having a decreased risk of breast cancer (OR=0.54, p<0.05); those with the combimed genotypes for the MnSOD 1183T>C C carrier and CAT -15A>T AA, and the combimed genotypes for the MnSOD 1183T>C C carrier and CAT -15A>T T carrier rather than those with the MnSOD 1183T>C TT and CAT -15A>T AA genotypes were predisposed to having a decreased risk of breast cancer (OR=0.56 and 0.55 respectively, p<0.05); those with the combimed genotypes for the MnSOD 1183T>C C carrier and CAT -262C>T CC rather than those with the MnSOD 1183T>C TT and CAT -262C>T CC genotypes were predisposed to having a decreased risk of breast cancer (OR=0.56, p<0.001); those with the combimed genotypes for the MnSOD 1183T>C C carrier and MPO -463G>A GG and the combimed genotypes for the MnSOD 1183T>C C carrier and MPO -463G>A A carrier genotypes rather than those with the MnSOD 1183 T>C TT and MPO -463G>A GG genotypes were predisposed to having a decreased risk of breast cancer (OR=0.49 and 0.43 respectively, p<0.001). ④ Those with the the combimed genotypes for the MnSOD 1183T>C TT and GPx1Pro198Leu T carrier and the combimed genotypes for the MnSOD 1183T>C C carrier and GPx1 Pro198Leu T carrier genotypes rather than those with the MnSOD 1183T>C TT and GPx1Pro198Leu CC genotypes were predisposed to having a decreased risk of breast cancer. (OR=0.22 and 0.07 respectively, p<0.001)
Conclusion: We suggested that the subjects with the CYP2E1-1053 T carrier、MnSOD 1183 C carrier, GPx1 T carrier have a decreased risk for breast cancer.
|
|---|
